The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10948-10957

  Rybak, Jascha N ^a   Roesli, Christoph ^a   Kaspar, Manuela ^a   Villa, Alessandra ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; PROTEIN EXTRA DOMAIN A; PROTEIN SUBUNIT; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; IMMUNOFLUORESCENCE; LIVER METASTASIS; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN VARIANT; SOLID TUMOR;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOPLASMS; PROTEOMICS; SPECTROPHOTOMETRY, INFRARED; TUMOR MARKERS, BIOLOGICAL;

EID: 36348980599     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1436     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57.
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
4. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
5. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
6. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
7. Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. Chem Med Chem 2007;2:22-40.
8. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
9. Huminiecki L, Bicknell R. In silico cloning of novel endothelial-specific genes. Genome Res 2000;10:1796-806.
10. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002;62:6132-40.
11. Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629-35.
12. Castronovo V, Waltregny D, Kischel P, et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006;5:2083-91.
13. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
14. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005;9:491-500.
15. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005;2:291-8.
16. Roesli C, Neri D, Rybak JN. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nature Protocols 2006;1:192-9.
17. Scheurer SB, Rybak J-N, Roesli C, et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005;5:2718-28.
18. Terrana B, Rusciano D, Pacenti L. Organ colonization pattern of retinoic acid-treated and -untreated mouse embryonal carcinoma F9 cells. Cancer Res 1987;47:3791-7.
19. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-76.
20. Giovannoni L, Viti F, Zardi L, Neri D. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res 2001;29:E27.
21. Borsi L, Castellani P, Allemanni G, Neri D, Zardi L. Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res 1998;240:244-51.
22. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-8.
23. Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 1999;231:239-48.
24. Berndorff D, Borkowski S, Moosmayer D, et al. Imaging of tumor angiogenesis using Tc-99m-labeled human recombinant Anti-ED-B fibronectin antibody fragments. Journal of nuclear medicine 2006;47:1707-16.
25. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
26. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331-9.
27. ffrench-Constant C. Alternative splicing of fibronectin - many different proteins but few different functions. Exp Cell Res 1995;221:261-71.
28. Bergijk EC, Baelde HJ, Kootstra CJ, De Heer E, Killen PD, Bruijn JA. Cloning of the mouse fibronectin V-region and variation of its splicing pattern in experimental immune complex glomerulonephritis. J Pathol 1996;178:462-8.
29. Silacci M, Brack S, Schirru G, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005;5:2340-50.
30. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5.
31. Niesner U, Halin C, Lozzi L, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002;13:729-36.
32. Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A. Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001;94:579-85.
33. Luster TA, He J, Huang X, et al. Plasma protein β-2-glycoprotein 1 mediates interaction between the antitumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 2006;281:29863-71.
34. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A 2005;102:355-60.
35. Esseghir S, Reis-Filho JS, Kennedy A, et al. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 2006;210:420-30.
36. Knox SM, Whitelock JM. Perlecan: how does one molecule do so many things? Cell Mol Life Sci 2006;63:2435-45.
37. Guelstein VI, Tchypysheva TA, Ermilova VD, Ljubimov AV. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int J Cancer 1993;53:269-77.
38. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7.
39. Gonzalez EM, Mongiat M, Slater SJ, Baffa R, Iozzo RV. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem 2003;278:38113-6.
40. Iozzo RV. Perlecan: a gem of a proteoglycan. Matrix Biol 1994;14:203-8.
41. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59:347-52.
42. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
43. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053-63s.
44. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J Biol Chem 1989;264:10331-4.
45. Matsumoto E, Yoshida T, Kawarada Y, Sakakura T. Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B+ by cancer cells and extra domain A+ by stromal cells. Jpn J Cancer Res 1999;90:320-5.
46. Borsi L, Carnemolla B, Castellani P, et al. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 1987;104:595-600.
47. Scarpino S, Stoppacciaro A, Pellegrini C, et al. Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J Pathol 1999;188:163-7.
48. Koukoulis GK, Shen J, Virtanen I, Gould VE. Immunolocalization of cellular fibronectins in the normal liver, cirrhosis, and hepatocellular carcinoma. Ultrastruct Pathol 1995;19:37-43.
49. Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen I. Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 1995;63:442-9.
50. Heikinheimo K, Morgan PR, Happonen RP, Stenman G, Virtanen I. Distribution of extracellular matrix proteins in odontogenic tumours and developing teeth. Virchows Arch B Cell Pathol Incl Mol Pathol 1991;61:101-9.